TP53 and neoplasm: In the first approach, the presence of ctDNA mutations in five genes (TP53, NOTCH1, CDKN2A, CASP8 and PTEN), previously identified in tumour samples, were examined in plasma, finding a total of 18 mutations in 42% of the patients, including those in the early stages.